Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money

69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

5 Top Stories

ARK’s Tesla Volte-Face; Record Tencent Buyback; Biotech Surges 99%

Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.

ARK’s Volte-Face on Tesla

The Tesla [TSLA] share price has dropped recently, closing down 4% on Wednesday. Nevertheless, Cathie Wood’s ARK Invest has started buying up Tesla shares — some 216,000 on 20 December and 3 January, according to Bloomberg — after spending much of last year selling them off. Elsewhere, short sellers are increasingly targeting BYD [BYDDF], which recently overtook Tesla as the world’s biggest EV maker.

Record Tencent Buyback

China’s most valuable company, Tencent [TCEHY], bought back HK$10bn of its shares in December, following the shock announcement of new regulations by China’s gaming regulator. Going into January, it has stepped up repurchases, spending HK$3bn so far this week, Bloomberg reported. The new rules include limits on in-game spending; fears that they presage a return to a more draconian regime prompted a major selloff of tech stocks.

Biotech Stock Surges 99% on NVO Deal

Blockbuster obesity drugmaker Novo Nordisk [NVO] has agreed to pay up to $1.1bn in research deals with two biotech firms backed by Flagship Pioneering, namely Omega Therapeutics [OMGA] and Cellarity; the Omega share price surged 99% on the news. The funds will be used to develop new technologies to fight obesity-related diseases. Novo is moving to expand it experimental pipeline and secure its predominance in the booming field of obesity treatments.

Disney: Ready for Battle?

As it readies itself for a showdown with activist investor Nelson Peltz, Walt Disney [DIS] has secured the support of another activist investor, ValueAct Capital, which built a stake in the entertainment giant last year. On Wednesday Disney said it had entered into an “information-sharing” agreement with ValueAct, while ValueAct said it would support Disney’s nominees for election at this year’s annual meeting. Meanwhile, Reuters reported that India’s Reliance Industries [RELIANCE:NS] and Disney are moving forward with their merger.

US Steps Up Domestic Chip Production

On Thursday the US Commerce Department said it will award $162m in government grants to Microchip Technology [MCHP], to help it increase domestic production. The funds will allow the chipmaker to triple production of mature-node semiconductor chips and microcontroller units, according to Reuters. The award “is a meaningful step in our efforts to bolster the supply chain for legacy semiconductors that are in everything,” Commerce Secretary Gina Raimondo said in a statement.

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

Latest articles